Unichem Laboratories Ltd

AGM Details

• 63rd AGM held on 11 August 2026 at 3:30 p.m. via Video Conference/Other Audio-Visual Means.

Resolutions

• Resolution 1 (Ordinary): Standalone financial statements adopted.
• Resolution 2 (Ordinary): Consolidated financial statements adopted.
• Resolution 3 (Ordinary): Director re-appointment – Pabitrakumar Bhattacharyya retires by rotation.
• Resolution 4 (Special): Re-appointment of MD/CEO Pabitrakumar Bhattacharyya for three years from 10 August 2026.
• Resolution 5 (Ordinary): Remuneration to Kishore Bhatia Associates for FY2027 ₹6,00,000 plus taxes.

Voting Results

• Resolution 1: Passed with overwhelming support; 11 votes against.
• Resolution 2: Passed; 12 votes against.
• Resolution 3: Passed; 440 against.
• Resolution 4: Passed; 440 against.
• Resolution 5: Passed; 12 against.

Directors

• Director changes: Pabitrakumar Bhattacharyya re-appointed; retires by rotation.

Auditors

• Cost Auditor remuneration approved: Kishore Bhatia Associates ₹6,00,000 for FY2027.

AGM Details

• AGM held on 11 August 2026 at 3:30 PM via video conference.
• Chair presided by Mr. Pranay Godha due to absence of Chairman.
• No proxies due to VC; voting conducted on NSDL platform.
• Scrutinizer appointed to declare results; results to stock exchanges and company website.

Key Resolutions

• Ordinary: Adopt standalone financial statements and reports; outcome not disclosed.
• Ordinary: Adopt consolidated financial statements and auditors’ report; outcome not disclosed.
• Ordinary: Re-appoint director by rotation; Bhattacharyya; outcome not disclosed.
• Special: Re-appointment of Bhattacharyya as Managing Director and CEO; outcome not disclosed.
• Ordinary: Ratify remuneration of cost auditors for year ending 31 March 2027; outcome not disclosed.

Auditor Arrangements

• Statutory auditors' report had no qualifications.
• Secretarial audit report had no qualifications.

Financials (Consolidated & Standalone, Q1 Jun 30 2026)

• Consolidated revenue from operations ₹632.62 crore; total income ₹648.23 crore in quarter ended 30 Jun 2026.
• Consolidated PAT after tax ₹41.47 crore; basic and diluted EPS ₹5.89.
• Standalone revenue from operations ₹366.27 crore; total income ₹382.99 crore.
• Standalone PAT ₹5.53 crore; standalone EPS ₹0.79.
• Operating segment is Pharmaceuticals with a single reportable segment.
• Invested ₹0.76 crore in Unichem China redeemable preference shares.

Filing Status

• Partial TRAN 1 credit allowed; Rs 73,02,757 disallowed; Rs 10,59,354 demand; order received 28 July 2026.
• No material impact; appeal to be filed within prescribed timelines.

GST TRAN 1 update

• Partial allowance of GSTR TRAN 1 credit; Rs 10,59,354 demand plus interest.
• Date of receipt 28 July 2026; no material financial impact; appeal within prescribed timelines.
• Original disallowance was Rs 73,02,757; partial relief reduces tax dispute.
• Authority: Additional Commissioner, CGST (Appeals), Dehradun.

Meeting Details

• Board meeting on 11 August 2026 to consider unaudited results for quarter ended 30 June 2026 (standalone/consolidated).

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for quarter ended 30 June 2026.

Other Notes

Price movement clarification

• Company states price rise is market-driven, complied with Reg 30 disclosures, and no undisclosed material information identified.